Parkman Healthcare Partners LLC Invests $14.32 Million in Xeris Biopharma Holdings, Inc. $XERS

Parkman Healthcare Partners LLC acquired a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,807,621 shares of the company’s stock, valued at approximately $14,316,000. Xeris Biopharma accounts for approximately 1.5% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 29th largest holding.

Other hedge funds also recently bought and sold shares of the company. Royal Bank of Canada increased its position in Xeris Biopharma by 1,411.2% during the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC boosted its position in Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP bought a new stake in shares of Xeris Biopharma during the 1st quarter valued at about $170,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Insider Activity at Xeris Biopharma

In other news, Director John Johnson sold 15,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the transaction, the director directly owned 683,083 shares in the company, valued at $4,159,975.47. The trade was a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the transaction, the insider owned 1,361,053 shares of the company’s stock, valued at $11,568,950.50. The trade was a 0.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 271,499 shares of company stock worth $2,038,917 in the last 90 days. Insiders own 4.35% of the company’s stock.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $8.74 on Tuesday. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $10.08. The stock’s fifty day moving average is $8.15 and its 200 day moving average is $6.88. The stock has a market cap of $1.59 billion, a P/E ratio of -79.45 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on XERS. Barclays increased their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Hold” and an average target price of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.